Dr. Ariel Kantor, PhDSVP, Head of Business and Corporate Development at ReCode TherapeuticsSpeaker
Profile
Dr. Kantor is a scientist, entrepreneur, and company builder with over 10 years of experience in the genetic medicines field. He is Senior Vice President and leads Business and Corporate Development at ReCode. Previously, Dr. Kantor served as an entrepreneur in residence at Oxford Science Enterprises, where he led company creation efforts and financings for several Oxford spinouts. Prior to Oxford, Dr. Kantor was an investment banker with Evercore Partners and a management consultant at Headland Strategy, advising on corporate strategy, M&A, and ECM transactions. Dr. Kantor has co-founded multiple companies in the fields of gene editing and RNA biology. In recognition of his technology developments, he was recognized in 2023 Forbes 30 under 30 in Science and Health Care. Dr. Kantor graduated from Duke University summa cum laude with a B.S. in bioengineering and finance and received his Ph.D. in Clinical Neuroscience from Oxford University, where he was a Rhodes Scholar.
Agenda Sessions
Panel Discussion: mRNA Therapies – The Next Chapter
, 4:15pmView SessionSelective Organ Targeting (SORT) Lipid Nanoparticle (LNP) Platform for Lung Delivery.
, 4:15pmView Session